NASDAQ:XENTIntersect ENT Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intersect ENT Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.15 -0.35 (-3.04 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$10.84Now: $11.15▼$11.4850-Day Range$9.10MA: $11.38▼$13.4952-Week Range$5.97Now: $11.15▼$31.46Volume251,715 shsAverage Volume446,868 shsMarket Capitalization$363.04 millionP/E RatioN/ADividend YieldN/ABeta1.14 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 4.0 Analyst's Opinion Consensus RatingIntersect ENT has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.38, Intersect ENT has a potential upside of 73.8% from its current price of $11.15.Amount of Analyst CoverageIntersect ENT has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesIntersect ENT has received 399 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntersect ENT has received 299 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntersect ENT has received 57.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote “Outperform” if you believe XENT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntersect ENT does not currently pay a dividend.Dividend GrowthIntersect ENT does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intersect ENT insiders have bought more of their company's stock than they have sold. Specifically, they have bought $295,863.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Intersect ENT is held by insiders.Percentage Held by Institutions87.72% of the stock of Intersect ENT is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intersect ENT are expected to grow in the coming year, from ($1.80) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intersect ENT is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intersect ENT is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntersect ENT has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENT Previous Symbol CUSIPN/A CIK1271214 Webwww.intersectent.com Phone650-641-2100Debt Debt-to-Equity Ratio0.10 Current Ratio6.63 Quick Ratio5.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$109.14 million Price / Sales3.33 Cash FlowN/A Price / Cash FlowN/A Book Value$3.31 per share Price / Book3.37Profitability EPS (Most Recent Fiscal Year)($1.37) Net Income$-42,990,000.00 Net Margins-48.61% Return on Equity-43.72% Return on Assets-36.28%Miscellaneous Employees393 Outstanding Shares32,560,000Market Cap$363.04 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:XENT Rates by TradingView Receive XENT News and Ratings via Email Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter. Intersect ENT (NASDAQ:XENT) Frequently Asked Questions How has Intersect ENT's stock been impacted by COVID-19 (Coronavirus)? Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENT shares have decreased by 48.1% and is now trading at $11.15. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Intersect ENT? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Intersect ENT. When is Intersect ENT's next earnings date? Intersect ENT is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intersect ENT. How were Intersect ENT's earnings last quarter? Intersect ENT Inc (NASDAQ:XENT) issued its quarterly earnings data on Monday, May, 11th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.10. The medical equipment provider had revenue of $19.83 million for the quarter, compared to the consensus estimate of $19.70 million. Intersect ENT had a negative net margin of 48.61% and a negative return on equity of 43.72%. View Intersect ENT's earnings history. What guidance has Intersect ENT issued on next quarter's earnings? Intersect ENT issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.5-19.8 million, compared to the consensus revenue estimate of $26.6 million. What price target have analysts set for XENT? 10 equities research analysts have issued 1-year price targets for Intersect ENT's shares. Their forecasts range from $10.00 to $30.00. On average, they anticipate Intersect ENT's stock price to reach $19.38 in the next year. This suggests a possible upside of 73.8% from the stock's current price. View analysts' price targets for Intersect ENT. Has Intersect ENT been receiving favorable news coverage? News coverage about XENT stock has been trending negative this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intersect ENT earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutIntersect ENT. Are investors shorting Intersect ENT? Intersect ENT saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,130,000 shares, an increase of 56.0% from the April 30th total of 724,200 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is currently 1.1 days. Approximately 3.6% of the company's stock are short sold. View Intersect ENT's Current Options Chain. Who are some of Intersect ENT's key competitors? Some companies that are related to Intersect ENT include Luminex (LMNX), Shockwave Medical (SWAV), Cardiovascular Systems (CSII), Axonics Modulation Technologies (AXNX), Silk Road Medical (SILK), Atrion (ATRI), Cerus (CERS), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Cryolife (CRY), Orthopediatrics (KIDS), Orthofix Medical (OFIX), GenMark Diagnostics (GNMK), Vapotherm (VAPO) and LeMaitre Vascular (LMAT). View all competitors. What other stocks do shareholders of Intersect ENT own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), COSTAMARE INC/SH (CMRE), Mimecast (MIME), Air Transport Services Group (ATSG), EOG Resources (EOG), AbbVie (ABBV), Gilead Sciences (GILD) and Netflix (NFLX). Who are Intersect ENT's key executives? Intersect ENT's management team includes the following people: Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)Ms. Christine R. Kowalski, Chief Operations Officer (Age 62) What is Intersect ENT's stock symbol? Intersect ENT trades on the NASDAQ under the ticker symbol "XENT." Who are Intersect ENT's major shareholders? Intersect ENT's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.03%), UBS Group AG (6.78%), Jennison Associates LLC (2.74%), State Street Corp (2.22%), Nuveen Asset Management LLC (1.80%) and Rock Springs Capital Management LP (1.54%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Richard E Kaufman, Robert H Binney, Jr, Susan P Stimson and Thomas A West. View institutional ownership trends for Intersect ENT. Which institutional investors are selling Intersect ENT stock? XENT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Rock Springs Capital Management LP, Waddell & Reed Financial Inc., Deutsche Bank AG, Nuveen Asset Management LLC, BlackRock Inc., Tudor Investment Corp Et Al, and Invesco Ltd.. Company insiders that have sold Intersect ENT company stock in the last year include Robert H Binney, Jr, and Susan P Stimson. View insider buying and selling activity for Intersect ENT. Which institutional investors are buying Intersect ENT stock? XENT stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Two Sigma Advisers LP, Two Sigma Investments LP, Balyasny Asset Management LLC, Jennison Associates LLC, Orbimed Advisors LLC, and AQR Capital Management LLC. Company insiders that have bought Intersect ENT stock in the last two years include Dana G Jr Mead, Richard A Meier, and Thomas A West. View insider buying and selling activity for Intersect ENT. How do I buy shares of Intersect ENT? Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Intersect ENT's stock price today? One share of XENT stock can currently be purchased for approximately $11.15. How big of a company is Intersect ENT? Intersect ENT has a market capitalization of $363.04 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Intersect ENT employs 393 workers across the globe. What is Intersect ENT's official website? The official website for Intersect ENT is www.intersectent.com. How can I contact Intersect ENT? Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
